News | June 16, 2009

Bayer Completes Phase II Study on Alzheimer's Disease Tracer

June 12, 2009 – Bayer Schering Pharma AG, Germany, has completed its first global Phase II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK) using positron emission tomography (PET) in patients with probable Alzheimer's disease compared to healthy volunteers. Information on BAY 94-9172 and related research and development programs will be presented during the Society of Nuclear Medicine (SNM) meeting in Toronto on June 13 - 17, 2009.

BAY 94-9172, currently in clinical development, is a 18F-labeled PET tracer and binds to beta amyloid, a protein that accumulates in the brain and that is considered being a pathological hallmark of Alzheimer's disease. Imaging with 18F-BAY 94-9172 should offer the possibility to support an early detection of Alzheimer's disease with an in-vivo imaging method.

"Beta amyloid has been proven to be a pathological hallmark of Alzheimer's disease and it is accumulated in the brain very early in the course of the disease. Currently, the detection of this protein and, thus, the definitive diagnosis of Alzheimer's disease is only possible upon post-mortem," said Thomas Balzer, M.D., head of Global Clinical Development Therapeutic Area Diagnostic Imaging. "Thus an in-vivo imaging method would be clinically very useful as it could help in the differentiation between different dementia forms and either exclude Alzheimer's disease or make it very likely. There is a high unmet medical need for a better and earlier differentiation between the various dementia forms and especially of Alzheimer's disease. We hope that BAY 94-9172 can contribute to this for the patient's benefit because an earlier and more accurate diagnosis allows for optimized care and treatment options," he added.

Bayer Schering Pharma has extended its Phase II program to further expand the number of imaged individuals and will also begin its pivotal Phase III global clinical development program of BAY 94-9172 in the second half of this year.

Related contributions at the Society of Nuclear Medicine (SNM) meeting in Toronto on June 13 - 17, 2009, include the following:

Test-retest variability of [18F]BAY94-9172 PET in Alzheimer's disease and normal ageing.
- Authors: Rowe, C.C.; Pejovska, S.; Mulligan, R.S.; Chan, G.; Jones, G.; Fels, L.; Kusi, H.; Reininger, C.; Rhode, B.; Putz, B.; O'Keefe, G.; Masters, C.L.; Villemagne, V.L.
Austin Hospital, Melbourne, VIC, Australia; Bayer Schering Pharma AG,
Berlin, Germany; The Mental Health Research Institute of Victoria, Melbourne, VIC, Australia.

- Scientific poster presentation at Neurology Posters, Poster Session I:
Multimodality and Non-Radioactive Molecular Imaging, Educational Exhibits, Cardiovascular & Neuroscience Track Posters.
Monday, June 15, 2:30 PM - 3:15 PM, Exhibit Hall E/F

Kinetic modeling of BAY94-9172 binding to beta-amyloid in human brains using PET data.
- Authors: Becker, G.; Barthel, H.; Luthardt, J.; Patt, M.; Hammerstein, E.; Eggers, B.; Reininger, C.; Rohde, B.; Hegerl, U.; Gertz, H.-J.; Sabri, O. Departments of Nuclear Medicine and Psychiatry, University of Leipzig, Arzneimittelforschung Leipzig Ltd., Bayer Schering Pharma AG, Berlin, Germany

- Oral presentation at Dementia II Session: Tracer Properties, Evaluation
Tuesday, June 16, 12:30 - 2 PM, Room 701A

Quantification of the radiation risk caused by [F18]BAY94-9172, a new PET tracer for detection of cerebral beta-amyloid plaques.
- Authors: Sattler, B.; Seese, A.; Barthel, H.; Patt, M.; Schildan, A.; Zollmann, F.; Reininger, C.; Rohde, B.; Eggers, B.; Gertz, H.-J.; Hegerl, U.; Sabri, O. University Hospital Leipzig, Dept. of Nuclear medicine; Bayer Schering Pharma AG, Berlin; University Hospital Leipzig, Dept. of Psychiatry; Pharmaceutical Research Leipzig GmbH

- Scientific poster presentation at Dosimetry/ISRTRD Posters.
Poster session IV: Radiopharmaceutical Chemistry Track Posters.
Tuesday, June 16 , 5:15 - 6:00 PM, Exhibit Hall E/F

Comparisons of Animal-Human Translated and Human 18F-BAY94-9172 Amyloid Radiation Dosimetry.
- Authors: O'Keefe, G.J.; Saunder, T.H.; Gong, S.; Pathmaraj, K.U.; Tochon-Danguy, H.T.; Villemagne, V.; Dyrks, T.; Dinkelborg, L.; Holl, G.; Rowe, C.C. Centre for PET, Austin Hospital, Heidelberg, Australia; Bayer Schering Pharma AG, Berlin, Germany
- Scientific poster presentation at Dosimetry/ISRTRD Posters: Posters Session IV: Radiopharmaceutical Chemistry Track Posters.
Tuesday, June 16, 5:15 - 6:00 PM, Exhibit Hall E/F

Related Content

Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....